Oncology

Latest News

Gen Li, PhD, MBA, president and founder of Phesi
Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

August 4th 2025

Digital patient profiles and expansive real-world data are reshaping oncology clinical trials, explained Gen Li, PhD, MBA, president and founder of Phesi.

Value-based care. | Image Credit: irissca - stock.adobe.com
Legal Navigation Services Key to Addressing Disparities in Cancer Care

July 31st 2025

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com
Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

July 30th 2025

As SCLC continues to pose a therapeutic challenge due to rapid progression and early metastasis, the convergence of immunotherapy and precision radiation holds promise to extend survival and improve outcomes. | Image credit: mi_viri - stock.adobe.com
Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

July 29th 2025

The findings suggest that inhibition of midkine might be a meaningful tool to improve treatment outcomes in SCLC. | Image credit: Pixel-Shot - stock.adobe.com
Midkine May Play Key Role in SCLC

July 24th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
August 5th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 5th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Estrogen | Image credit: Debalina - stock.adobe.com
March 20th 2025

Estrogen Therapy May Increase Risk of 3 Skin Cancers

Hayden E. Klein
Researchers of a Swedish study advise physicians to consult with their patients about these risks and take extra precautions, but did not recommend discontinuation of any of the drugs studied.
Karen Winkfield, MD, PhD
March 19th 2025

Expanding Access to Clinical Trials Through Community Partnerships

Maggie L. Shaw Karen Winkfield, MD, PhD
Karen Winkfield, MD, PhD, addresses the importance of meeting patients where they are to expand clinical trial participation and remove barriers to trial access.
Texas Oncology logo | Image: Texas Oncology
March 18th 2025

Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot

Mary Caffrey Rose McNulty
Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Cancer Labels on Alcohol? Ireland, Where Pubs Still Rule, Will Have Them by Next Year
March 17th 2025

Cancer Labels on Alcohol? Ireland, Where Pubs Still Rule, Will Have Them by Next Year

Mary Caffrey
As St. Patrick's Day brings global celebrations involving alcohol, Ireland looks forward to rethinking excess consumption with a new tool set to arrive next year: the world's most comprehensive alcohol warning label.
Jorge García, PharmD, MS, MBA, MHA, FACHE, FACCC
March 15th 2025

How Do Infusion Pharmacies Support Financial Sustainability in Oncology?

Hayden E. Klein Jorge García, PharmD, MS, MBA, MHA, FACHE, FACCC
Jorge García, PharmD, MS, MBA, MHA, highlights the need for infusion pharmacy optimization to sustain oncology care amid rising costs and evolving value-based reimbursement models.
Doctor screening patient for skin cancer | Image credit: Seventyfour – stock.adobe.com
March 14th 2025

Patients Prefer AI in Skin Cancer Screening as an Assistive Tool, Not a Replacement

Hayden E. Klein
Patients expressed concern that overreliance on artificial intelligence (AI) could lead to clinicians losing their skills, both medical and interpersonal.
The Weapons of Getting Paid: Bringing Data, Technology, and Advocacy to the Battle
March 9th 2025

The Weapons of Getting Paid: Bringing Data, Technology, and Advocacy to the Battle

Mary Caffrey
Experts shared details on health care contracting, setting up a centralized prior authorization pilot, and use of advocacy to win pharmacy benefit manager reforms at the state level.
Doctor conducting a skin cancer check | Image credit: InsideCreativeHouse - stock.adobe.com
March 6th 2025

Image-Guided Superficial Radiation Therapy Safe, Effective Treatment for Nonmelanoma Skin Cancer: Expert Panel

Emma Andrus
A dermatology expert panel confirms image-guided superficial radiation therapy as a safe, effective first-line treatment for select nonmelanoma skin cancer cases.
lung cancer | Image credit: Crystal light - stock.adobe.com
March 5th 2025

Study Launches Exploring Peluntamig Combo in DLL3-Expressing Tumors

Jordyn Sava
Dosing has started in a clinical evaluating peluntamig, which targets DLL3 and CD47, combined with chemotherapy in patients with DLL3-expressing small cell lung cancer and neuroendocrine carcinoma.
DNA strand | Image: FreePik
March 4th 2025

Technology, Partnerships, Data, and Culture Are Keys to Bringing Precision Medicine to Community Oncology

Mary Caffrey
First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1
Published: March 4th 2025 | Updated: March 4th 2025

First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1

Rose McNulty
Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1.
Screenshot of an interview with Shaun McKenzie, MD
March 2nd 2025

Identifying Good Candidates for Histotripsy to Treat Liver Tumors

Laura Joszt, MA Shaun P. McKenzie, MD, FACS
Some patients are better candidates than others for histotripsy to treat liver tumors, but ultimately, this treatment still requires a good multidisciplinary team, like any cancer treatment, said Shaun P. McKenzie, MD, FACS.
Karen Winkfield, MD, PhD
March 2nd 2025

Expanding Clinical Trial Access Amid DEI Challenges

Maggie L. Shaw Karen Winkfield, MD, PhD
Karen Winkfield, MD, PhD, addresses the importance of inclusive clinical trial participation and meeting patients where they are.
Blue cancer ribbon | Image credit: Chinnapong - stock.adobe.com
February 26th 2025

Cetuximab Plus Chemotherapy May Improve Colorectal Cancer Outcomes

Pearl Steinzor
When combined with chemotherapy, cetuximab shows promising efficacy for optimizing treatment strategies for patients with metastatic colorectal cancer.
Chelsee Jensen, PharmD, BCPS | Image credit: LinkedIn
February 24th 2025

Price Caps During Accelerated Approval Would Help Address Financial Toxicity for Patients, Jensen Says

Chelsee J. Jensen, PharmD, BCPS Interview by Mary Caffrey
Health care institutions with large numbers of Medicare and Medicaid patients may be constrained from offering cancer therapies made available under the accelerated approval pathway.
Cervical cancer awareness | Image Credit: © WhalewithMoon-stock.adobe.com
February 24th 2025

Health System Policy Failures Drive Cervical Cancer Disparities in Rural South

Maggie L. Shaw
The Southern Rural Black Women’s Initiative for Economic and Social Justice works to overcome race, class, cultural, religious, and gender barriers that Black women and young women face in the rural South, specifically the Mississippi Delta and the Black Belt regions of Alabama and Georgia.
Screenshot of an interview with Shaun McKenzie, MD
February 23rd 2025

Histotripsy May Expand Beyond Liver Tumors, but Long-Term Data Are Still Needed

Laura Joszt, MA Shaun P. McKenzie, MD, FACS
Although histotripsy can successfully destroy tumors in the liver, longer-term data are still needed to see recurrence rates and overall survival, said Shaun P. McKenzie, MD, FACS, a surgical oncologist with Texas Oncology.
Screenshot of an interview with Rohan Garje, MD
February 21st 2025

Barriers That Prevent Access to Optimal Treatment in Primary Urethral Cancer

Laura Joszt, MA Rohan Garje, MD
Eligibility issues, a need for better multidisciplinary collaboration, and a lack of incorporation in community practices are all barriers to the use of neoadjuvant chemotherapy followed by surgery for patients with primary urethral cancer, said Rohan Garje, MD.
Susan Escudier, MD, FACP
February 21st 2025

The Need for Payer Support in Overcoming Cancer Care Disparities

Hayden E. Klein Susan Escudier, MD, FACP
Susan Escudier, MD, FACP, discusses the impact of insurance coverage gaps, transportation barriers, and financial hardships on cancer care access and emphasizes the need for payers to better support patients at high risk.
Alicia Morgans MD, MPH | Image credit: Dana-Farber
February 20th 2025

Getting More Doctors to Record a Life-Saving Prostate Cancer Calculation

Mary Caffrey
Accurate calculation of prostate-specific antigen doubling time can be crucial for prostate cancer treatment decisions but is often missed by doctors, impacting patient care.
Sabarish Ayyappan, MD
February 20th 2025

Geographic Barriers Impede Access to Novel Cancer Treatments

Kyle Munz Sabarish Ayyappan, MD
In the wake of novel bispecific and chimeric antigen receptor T-cell therapies for various cancers, geography still plays a big role in patients' abilities to receive such treatments.
Fueling Cancer Research Breakthroughs With Patient Contributions
February 20th 2025

Fueling Cancer Research Breakthroughs With Patient Contributions

Maggie L. Shaw Karen Winkfield, MD, PhD
In part 3 of this conversation, Karen Winkfield, MD, PhD, executive director of the Meharry-Vanderbilt Alliance, discusses why basic scientific research remains essential and how patient experiences contribute.
Patient talking with doctor | Image credit: Monkey Business - stock.adobe.com
February 20th 2025

Cancer Mortality Rates Still High Among Black Patients, Despite Overall Decline

Julia Bonavitacola
Black individuals had a 2-fold risk of cancer death related to prostate, myeloma, and stomach cancers compared with White individuals.
Vivek Murthy, MD | Image credit: NBC News
February 19th 2025

Alcohol and Cancer Risk: Murthy’s Parting Call for Warning Labels

Maggie L. Shaw
radiology x-ray lung cancer | Image credit: utah51 – stock.adobe.com
February 17th 2025

2 Immunotherapies Show Comparable Benefits in Extensive-Stage Small Cell Lung Cancer

Hayden E. Klein
When added to chemotherapy, researchers found no significant difference in overall or progression-free survival between PD-1 and PD-L1 inhibitors.
Susan Escudier, MD, FACP
February 17th 2025

Addressing Financial Toxicity and Clinical Trial Disparities in Community Oncology

Hayden E. Klein Susan Escudier, MD, FACP
Susan Escudier, MD, FACP, explains some of the ways Texas Oncology mitigates financial toxicity and improve clinical trial access for underserved patients.
Powles Highlights “Transformative” Benefit of EV Plus Pembro While Sharing Long-Term Data for EV-302
February 15th 2025

Powles Highlights “Transformative” Benefit of EV Plus Pembro While Sharing Long-Term Data for EV-302

Mary Caffrey
The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered an achievement; in this study, median overall survival was 34 months after treatment with enfortumab vedotin (EV) and pembrolizumab (pembro).
Analysis Looks at Benefits, Toxicity of ADC Combinations in Advanced Bladder Cancer
February 15th 2025

Analysis Looks at Benefits, Toxicity of ADC Combinations in Advanced Bladder Cancer

Mary Caffrey
City of Hope's Salvador Jaime-Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody-drug conjugate (ADC) combinations in advanced urothelial cancer.
Screenshot of an interview with Evangelia Vlachou, MD
February 14th 2025

Enfortumab Vedotin With or Without Pembrolizumab Delivers Promising Responses for Upper Tract Urothelial Cancer

Laura Joszt, MA Evangelia Vlachou, MD
Enfortumab vedotin with or without pembrolizumab offers disease control benefits for patients with upper tract urothelial cancer, said Evangelia Vlachou, MD, of Johns Hopkins Medicine.
Screenshot of an interview with Barry Goy, MD
Published: February 14th 2025 | Updated: February 14th 2025

Receiving NADT for 6 Months Doesn’t Impact Outcomes in Intermediate-Risk Prostate Cancer After EBRT

Laura Joszt, MA Barry Goy, MD
Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk prostate cancer treated with external-beam radiation therapy (EBRT), according to 15-year outcomes presented by Barry Goy, MD, of Kaiser Permanente.
<12345678
...
187>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo